Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors
This study is ongoing, but not recruiting participants.
Study NCT00003518 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Cancer
Testicular Germ Cell Tumor
Additional conditions recognized in this trial
Neoplasms, Germ Cell and Embryonal
Ovarian Neoplasms
More general conditions related to this trial
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Interventions listed in this trial
gemcitabine hydrochloride
paclitaxel
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Back to top of Main Content
